{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"111"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"184"}],"units":"Participants"}],"description":"The number of participants with objective response was assessed every six weeks from Cycle 1 Day 1 through discontinuation of treatment, by independent central imaging facility review based on RECIST version 1.1.","groups":[{"description":"All T-DM1 resistant/refractory (R/R) participants who were treated in Part 1 or Part 2a at the recommended (5.4 mg/kg) dose.","id":"OG000","title":"Part 1 and Part 2a: DS-8201a Low Dose"},{"description":"All participants who were previously treated with T-DM1 and were randomized to receive DS8201a low dose (5.4 mg/kg) in Part 1 or Part 2a or Part 2b.","id":"OG001","title":"Part 1 + Part 2a + Part 2b: DS-8201a Low Dose"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Objective response rate (ORR) was assessed in the Enrolled Analysis Set.at data cut-off date of 21 March 2019","reportingStatus":"POSTED","timeFrame":"at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)","title":"Objective Response Rate as Confirmed by Independent Central Review Following Intravenous Administration of 5.4 mg/kg DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)","type":"PRIMARY","unitOfMeasure":"Participants"}